Komori
Solasia Pharma K.K. (4597) · FactWorsened

Quarterly Profitability in the Third Quarter

First written in FY2017-Q3. 5 of 9 entries say "Worsened", first in FY2018-Q3. Latest entry: FY2024-H1.

9entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017-Q3WorsenedFY2018-Q3RestatedFY2019-Q3WorsenedFY2020-Q3 – FY2022-Q3RestatedFY2022 – FY2023-Q32017: 12018: 120182019: 120192020: 120202021: 120212022: 120222023: 220232024: 12024
Same theme, other companies

Solasia Pharma K.K. moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.

The whole theme swung hardest in 2020: 28 of 87 companies on the "Worse" side.

23 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 108 companies compared. The sentences above are computed from all 108.
Full recordFilings, disclosures and news, newest first
  1. FY2024-H1WorsenedAnnual report

    「四半期利益(△損失) △196 △300」

    第2四半期会計期間単体の親会社所有者帰属四半期損失は、前年同期の196百万円から300百万円へ拡大し、四半期単位の赤字が継続した。
  2. FY2023-Q3四半期赤字縮小Annual report

    「親会社の所有者に帰属する四半期利益(△損失) △801 △331」

    第3四半期会計期間単体の親会社所有者帰属四半期損失は前年同期の801百万円から331百万円へ縮小したが、四半期単体の赤字は継続している。
  3. FY2022RestatedAnnual report

    「△2.97」

    第4四半期の基本的1株当たり四半期損失は2.97円となり、第3四半期会計期間単体の黒字化は確認されないまま、四半期単位の赤字が継続している。
  4. FY2022-Q3WorsenedAnnual report

    「親会社の所有者に帰属する四半期利益(△損失) △716 △801」

    第3四半期会計期間単体の親会社所有者帰属四半期損失は、前年同期の716百万円から801百万円へ拡大し、単体赤字が継続した。
  5. FY2021-Q3WorsenedAnnual report

    「四半期利益(△損失) △665 △716」

    第3四半期会計期間単体の損失は前年同期の665百万円から716百万円へ拡大し、四半期単体の赤字が続いている。
  6. FY2020-Q3WorsenedAnnual report

    「四半期利益(△損失) △579 △665」

    第3四半期会計期間単体の損失は前年同期の579百万円から665百万円へ拡大し、四半期単体の赤字が続いている。
  7. FY2019-Q3RestatedAnnual report

    「四半期利益(△損失) △617 △579」

    第3四半期会計期間単体の損失は前年同期の617百万円から579百万円へ縮小したが、黒字化には至らず、四半期単体の赤字状態が続いている。
  8. FY2018-Q3WorsenedAnnual report

    「四半期利益(△損失) 134 △617」

    前年同期の第3四半期会計期間が134百万円の利益だったのに対し、当第3四半期会計期間は617百万円の損失となり、四半期単体の黒字状態から赤字へ変化した。
  9. FY2017-Q3First statedAnnual report

    「Third-quarter accounting period: quarterly profit (loss) ¥134.343 million」

    For the standalone third-quarter accounting period from 1 July to 30 September 2017, the Company recorded operating profit of ¥128.631 million and quarterly profit of ¥134.343 million. However, an operating loss and quarterly loss continued for the nine-month period.
Moved together

"Risk of Shareholder Dilution from New Share Issuances and Stock Acquisition Rights" moved the same way as this thread, in the same document, in 5 of its 9 moves.

542★123
  1. ★This thread
  2. 1Risk of Shareholder Dilution from New Share Issuances and Stock Acquisition Rights5×
  3. 2Upfront Investment, Continuing Losses and Cash Management4×
  4. 3Restrictions on Business Activities Due to COVID-192×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.